Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
ADScreen, a speech-processing algorithm developed at Columbia Nursing, is now being tested in a clinical trial to see if it can help health care workers identify patients with Alzheimer's earlier.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.
Ancient parts of the brain may hold secrets that help explain the drive to eat and how eating may affect brain health. Sabrina Diano, the new Institute of Human Nutrition director, is investigating.
A new study of Alzheimer’s genes suggests the disease in Blacks and whites is largely the same, but genetic changes that increase the risk of developing the disease differ between the two groups.
A newly discovered Alzheimer’s gene appears to drive the first appearance of amyloid plaque in the brain and could lead to new therapies that prevent the disease from developing.
A new study shows how modifications to the tau protein may influence the different ways it can misfold in the brain, which is closely linked to the type of neurodegenerative disease that develops.
Researchers had high hopes for Alzheimer’s drugs that clear amyloid from the brain, but none of the drugs have slowed the disease. Columbia’s Scott Small says he has new reasons to be optimistic.
A new study from Columbia University found that a higher level of education protected against cognitive decline in black people with a gene linked to Alzheimer’s disease.
A new study shows how cellular “housekeeping” protects some neurons against the toxic proteins of Alzheimer’s disease and suggests new treatment possibilities.